


DESCRIPTION	
Species Reactivity	Feline
Specificity	Detects feline IL-6 in direct ELISAs and Western blots. In direct ELISAs and Western blots, 25% cross-reactivity with recombinant canine IL-6 is observed and no cross-reactivity with recombinant human (rh) IL-6, recombinant mouse (rm) IL-6, recombinant porcine IL-6, recombinant equine IL-6, recombinant rat IL-6, rhCLC, rmlLIF, rmOSM, or rmCT-1 is observed.
Source	Monoclonal Mouse IgG _{2B} Clone # 341041
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant feline IL-6 Thr28-Met208 (Glu133Lys) Accession # P41683
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

APPLICATIONS		
<i>Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.</i>		
	Recommended Concentration	Sample
Western Blot	1 µg/mL	Recombinant Feline IL-6 (Catalog # 2305-FL)
Neutralization	Measured by its ability to neutralize IL-6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. Nordan, R. P. and M. Potter (1986) Science 233 :566. The Neutralization Dose (ND ₅₀) is typically 3-10 µg/mL in the presence of 10 ng/mL Recombinant Feline IL-6.	



PREPARATION AND STORAGE	
Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Interleukin 6 (IL-6) is a pleiotropic α -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is central to the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22 kDa-28 kDa phosphorylated and variably glycosylated molecule (1-4). Mature feline IL-6 is 181 amino acids (aa) in length and shares 76%, 58%, 39%, and 41% aa sequence identity with canine, human, mouse, and rat IL-6, respectively (5). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (6). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (7). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL-6 R (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 8).

References:

1. Van Snick, J. (1990) *Annu. Rev. Immunol.* **8**:253.
2. Hodge, D.R. *et al.* (2005) *Eur. J. Cancer* **41**:2502.
3. Jones, S.A. (2005) *J. Immunol.* **175**:3468.
4. Rose-John, S. *et al.* (2006) *J. Leukoc. Biol.* **80**:227.
5. Ohashi, T. *et al.* (1993) *J. Vet. Med. Sci.* **5**:941.
6. Murakami, M. *et al.* (1993) *Science* **260**:1808.
7. Muller-Newen, G. (2003) *Sci. STKE* **2003**:PE40.
8. Mitsuyama, K. *et al.* (2006) *Clin. Exp. Immunol.* **143**:125.